Literature DB >> 6610478

Characterization of interleukin 2 (IL-2)-dependent cytotoxic T-cell clones. V. Transfer of resistance to allografts and tumor grafts requires exogenous IL-2.

M A Palladino, K Welte, A M Carroll, H F Oettgen.   

Abstract

The adoptive transfer of resistance to tumor grafts with cloned interleukin 2 (IL-2)-dependent cytotoxic T-cell lines was examined. Two clones were used: clone CTLL-A2 which recognizes H-2Dd determinants and clone CTLL-R5 which recognizes a unique cell surface antigen of BALB/c leukemia RL male 1. Systemic transfer of resistance with these clones was accomplished only when exogenous (rat or human) IL-2 was administered at the same time. Intraperitoneal injection of CTLL-A2 cells accelerated rejection of sarcoma Meth A (H-2Dd), but not ascites sarcoma BP8 (H-2k) or leukemia EL4 (H-2b) inoculated subcutaneously into C57BL/6 mice. CTLL-R5 cells were examined in local (Winn tests) as well as systemic transfer experiments. When mixed with leukemia cells before subcutaneous injection, they suppressed the growth of leukemia RL male 1 without exogenous IL-2. When injected intraperitoneally, CTLL-R5 cells inhibited the growth of subcutaneous grafts of leukemia RL male 1 only when exogenous IL-2 was administered at the same time. CTLL-R5 did not inhibit the growth of other radiation-induced BALB/c leukemias.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610478     DOI: 10.1016/0008-8749(84)90384-8

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

1.  Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells.

Authors:  K Oomori; Y Kikuchi; M Miyauchi; T Kita; I Iwano; I Kizawa; J Hirata; E Kuki
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

2.  Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Authors:  S D Voss; J A Hank; C A Nobis; P Fisch; J A Sosman; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  The toxicity of recombinant human interleukin-2 in rats following intravenous infusion.

Authors:  Y L Matory; A E Chang; E H Lipford; R Braziel; C L Hyatt; S A Rosenberg
Journal:  J Natl Med Assoc       Date:  1987-05       Impact factor: 1.798

4.  Effector mechanisms of syngeneic anti-tumour responses in mice. II. Cytotoxic T lymphocytes mediate neutralization and rejection of radiation-induced leukaemia RL male 1 in the nude mouse system.

Authors:  A Keyaki; K Kuribayashi; S Sakaguchi; T Masuda; J Yamashita; H Handa; E Nakayama
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

5.  Transfer of murine host protection by using interleukin-2-dependent T-lymphocyte lines.

Authors:  C C Paul; K Norris; R Warren; R A Smith
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

6.  Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.

Authors:  M A Cheever; D B Thompson; J P Klarnet; P D Greenberg
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.